Focal therapy of prostate cancer: Evidence-based analysis for modern selection criteria

Current Urology Reports

Volumn 13, Issue 2, 2012, Pages 160-169

  Abern, Michael R ^a   Tsivian, Matvey ^a   Polascik, Thomas J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Focal therapy; Patient selection; Prostate cancer; Prostate specific antigen; Transperineal threedimensional mapping; Transrectal ultrasound

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BRACHYTHERAPY; CANCER GRADING; CANCER MORTALITY; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER THERAPY; COMORBIDITY; CONTRAST ENHANCEMENT; CRYOHEMIABLATION; DISTANT METASTASIS; EVIDENCE BASED PRACTICE; FOCAL THERAPY; GLEASON SCORE; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; MAGNETIC RESONANCE GUIDED LASER THERMAL FOCAL ABLATION; MAGNETIC RESONANCE GUIDED ULTRASOUND FOCAL ABLATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATIENT SELECTION; PHOTOTHERMAL LASER FOCAL ABLATION; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RADIOFREQUENCY HEMIABLATION; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR ABLATION; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; CRYOSURGERY; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOHISTOCHEMISTRY; LASER THERAPY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SURGICAL PROCEDURES, MINIMALLY INVASIVE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL;

EID: 84860735666     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-012-0241-5     Document Type: Review

References (67)

1. Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force. Available at http://www. uspreventiveservicestaskforce.org/uspstf12/prostate/prostateart.htm. Accessed January 2012.
2. Eggener SE, Scardino PT, Carroll PR, Zelefsky MJ, Sartor O, Hricak H, et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol. 2007;178 (6):2260-7. (Pubitemid 350052204)
3. de la Rosette J, Ahmed H, Barentsz J, Johansen TB, Brausi M, Emberton M, et al. Focal therapy in prostate cancer-report from a consensus panel. J Endourol. 2010;24(5):775-80.
4. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280 (11):969-74. (Pubitemid 28445094)
5. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271(5):368-74. (Pubitemid 24037911)
6. Onik G, Vaughan D, Lotenfoe R, Dineen M, Brady J. The "male lumpectomy": focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up. Urol Oncol. 2008;26(5):500-5.
7. Lambert EH, Bolte K, Masson P, Katz AE. Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer. Urology. 2007;69(6):1117-20. (Pubitemid 46891597)
8. Ellis DS, Manny Jr TB, Rewcastle JC. Focal cryosurgery followed by penile rehabilitation as primary treatment for localized prostate cancer: initial results. Urology. 2007;70(6 Suppl):9-15.
9. Bahn DK, Silverman P, Lee Sr F, Badalament R, Bahn ED, Rewcastle JC. Focal prostate cryoablation: initial results show cancer control and potency preservation. J Endourol. 2006;20 (9):688-92. (Pubitemid 46140997)
10. Tsivian M, Moreira DM, Sun L, Mouraviev V, Kimura M, Moul JW et al. Biopsy accuracy in identifying unilateral prostate cancer depends on prostate weight. Urol Oncol 2010.
11. Arvold ND, Chen MH, Moul JW, Moran BJ, Dosoretz DE, Banez LL, et al. Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease. J Urol. 2011;186(1):91-6.
12. Hofner T, Pfitzenmaier J, Alrabadi A, Pahernik S, Hadaschik B, Wagener N et al. PSA density lower cutoff value as a tool to exclude pathologic upstaging in initially diagnosed unilateral prostate cancer: impact on hemiablative focal therapy. World J Urol 2010.
13. Palma D, Tyldesley S, Pickles T. Pretreatment prostate-specific antigen velocity is associated with development of distantmetastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy. Cancer. 2008;112(9):1941-8. (Pubitemid 351574069)
14. Ketchandji M, Kuo YF, Shahinian VB, Goodwin JS. Cause of death in older men after the diagnosis of prostate cancer. J Am GeriatrSoc. 2009;57(1):24-30.
15. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009;302(11):1202-9.
16. El Fegoun AB, Barret E, Prapotnich D, Soon S, Cathelineau X, Rozet F, et al. Focal therapy with high-intensity focused ultrasound for prostate cancer in the elderly. A feasibility study with 10 years follow-up. Int Braz J Urol. 2011;37(2):213-9. discussion 220-212.
17. Scattoni V, Raber M, Capitanio U, Abdollah F, Roscigno M, Angiolilli D, et al. The optimal rebiopsy prostatic scheme depends on patient clinical characteristics: results of a recursive partitioning analysis based on a 24-core systematic scheme. Eur Urol. 2011;60 (4):834-41.
18. Tsivian M, Kimura M, Sun L, Mouraviev V, Mayes JM, Polascik TJ. Predicting unilateral prostate cancer on routine diagnostic biopsy: sextant vs extended. BJU Int 2009.
19. King AC, Livermore A, Laurila TA, Huang W, Jarrard DF. Impact of immediate TRUS rebiopsy in a patient cohort considering active surveillance for favorable risk prostate cancer. Urol Oncol 2011
20. Berglund RK, Masterson TA, Vora KC, Eggener SE, Eastham JA, Guillonneau BD. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol. 2008;180(5):1964-7. discussion 1967-1968.
21. Tseng KS, Landis P, Brimo F, Partin AW, Epstein JI, Carter HB. Repeat prostate biopsies predict location of index cancer in an active surveillance cohort. BJU Int. 2011;108(9):1415-20.
22. Abdollah F, Novara G, Briganti A, Scattoni V, Raber M, Roscigno M, et al. Trans-rectal versus trans-perineal saturation rebiopsy of the prostate: is there a difference in cancer detection rate? Urology. 2011;77(4):921-5.
23. Taira AV, Merrick GS, Galbreath RW, Andreini H, Taubenslag W, Curtis R, et al. Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting. Prostate Cancer Prostatic Dis. 2010;13 (1):71-7.
24. Abdollah F, Scattoni V, Raber M, Roscigno M, Briganti A, Suardi N, et al. The role of transrectal saturation biopsy in tumour localization: pathological correlation after retropubic radical prostatectomy and implication for focal ablative therapy. BJU Int. 2011;108 (3):366-71.
25. Ahmed HU, Hu Y, Carter T, Arumainayagam N, Lecornet E, Freeman A, et al. Characterizing clinically significant prostate cancer using template prostate mapping biopsy. J Urol. 2011;186 (2):458-64.
26. •• Barqawi AB, Rove KO, Gholizadeh S, O'Donnell CI, Koul H, Crawford ED. The role of 3-dimensional mapping biopsy in decision making for treatment of apparent early stage prostate cancer. J Urol. 2011;186(1):80-5. This series reports high upgrade and upstage rates with TPM biopsy relative to standard TRUS biopsy. Pending correlation with whole-mount pathology will be critical to quantify the accuracy for FT applications.
27. Ahmed HU, Freeman A, Kirkham A, Sahu M, Scott R, Allen C, et al. Focal therapy for localized prostate cancer: a phase I/II trial. J Urol. 2011;185(4):1246-54.
28. Tsivian M, Hruza M, Mouraviev V, Rassweiler J, Polascik TJ. Prostate biopsy in selecting candidates for hemiablative focal therapy. J Endourol. 2010;24(5):849-53.
29. Roethke M, Anastasiadis AG, Lichy M, Werner M, Wagner P, Kruck S, et al. MRI-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy. World J Urol 2011.
30. •• Ouzzane A, Puech P, Lemaitre L, Leroy X, Nevoux P, Betrouni N, et al. Combined Multi-parametric MRI and Targeted Biopsies Improve Anterior Prostate Cancer Detection, Staging, and Grading. Urology 2011. The authors describes that biopsies targeted to suspicious Mp-MRI findings in the anterior and central prostate have a high rate of accuracy.
31. Pinto PA, Chung PH, Rastinehad AR, Baccala Jr AA, Kruecker J, Benjamin CJ, et al. Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multi-parametric magnetic resonance imaging. J Urol. 2011;186(4):1281-5.
32. ClinicalTrials.gov. Pilot Study on Focal Prostate Radio-Frequency Ablation. Available at http://clinicaltrials.gov/ct2/show/ NCT01423006. Accessed January 2012.
33. Focal MR-Guided Focused Ultrasound Treatment of Localized Low-Risk Prostate Cancer: Feasibility Study [http://clinicaltrials.gov/ct2/show/ NCT01226576]
34. Assessing the Potential for Reduced Toxicity Using Focal Brachytherapy in Low-Risk Prostate Cancer [http://clinicaltrials.gov/ct2/ show/NCT01354951]
35. Lindner U, Weersink RA, Haider MA, Gertner MR, Davidson SR, Atri M, et al. Image guided photothermal focal therapy for localized prostate cancer: phase I trial. J Urol. 2009;182 (4):1371-7.
36. • Truesdale MD, Cheetham PJ, Hruby GW, Wenske S, Conforto AK, Cooper AB, et al. An evaluation of patient selection criteria on predicting progression-free survival after primary focal unilateral nerve-sparing cryoablation for prostate cancer: recommendations for follow up. Cancer J. 2010;16(5):544-9. This report highlights the limitations of selecting patients for FT based on standard biopsy schemes and preoperative clinical parameters.
37. Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, et al. Gleason score and lethal prostate cancer: does 3 + 4 0 4 + 3? J ClinOncol. 2009;27(21):3459-64.
38. Turkbey B, Mani H, Shah V, Rastinehad AR, Bernardo M, Pohida T, et al. Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol. 2011;186(5):1818-24.
39. Raz O, Haider MA, Davidson SR, Lindner U, Hlasny E, Weersink R, et al. Real-time magnetic resonance imaging-guided focal laser therapy in patients with low-risk prostate cancer. Eur Urol. 2010;58(1):173-7.
40. Mouraviev V, Villers A, Bostwick DG, Wheeler TM, Montironi R, Polascik TJ. Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy. BJU Int. 2011;108 (7):1074-85.
41. Onik G, Miessau M, Bostwick DG. Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J ClinOncol. 2009;27(26):4321-6.
42. Ahmed HU. The index lesion and the origin of prostate cancer. N Engl J Med. 2009;361(17):1704-6.
43. •• Karavitakis M, Winkler M, Abel P, Livni N, Beckley I, Ahmed HU. Histological characteristics of the index lesion in wholemount radical prostatectomy specimens: implications for focal therapy. Prostate Cancer Prostatic Dis. 2011;14(1):46-52. This article describes pathological characterization of CaP foci that supports the theory that the primary or index lesion accounts for most significant disease.
44. Bott SR, Ahmed HU, Hindley RG, Abdul-Rahman A, Freeman A, Emberton M. The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer. BJU Int. 2010;106 (11):1607-11.
45. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer Cancer. 1993;71(3 Suppl):933-8.
46. ClinicalTrials.gov. Laser Based Focal Ablation of Low Grade Prostate Cancer. Available at http://clinicaltrials.gov/ct2/show/ NCT01192438. Accessed January 2012.
47. ClinicalTrials.gov. MRI Targeted Focal Laser Thermal Therapy of Prostate Cancer (FLTT 002) Available at http://clinicaltrials.gov/ ct2/show/NCT01094665. Accessed January 2012.
48. ClinicalTrials.gov. MR Image Guided Therapy in Prostate Cancer. Available at [http://clinicaltrials.gov/ct2/show/NCT01377753. Accessed January 2012.
49. Nogueira L, Wang L, Fine SW, Pinochet R, Kurta JM, Katz D, et al. Focal treatment or observation of prostate cancer: pretreatment accuracy of transrectal ultrasound biopsy and T2-weighted MRI. Urology. 2010;75(2):472-7.
50. Jackson AS, Reinsberg SA, Sohaib SA, Charles-Edwards EM, Jhavar S, Christmas TJ, et al. Dynamic contrast-enhanced MRI for prostate cancer localization. Br J Radiol. 2009;82 (974):148-56.
51. Puech P, Potiron E, Lemaitre L, Leroy X, Haber GP, Crouzet S, et al. Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens. Urology. 2009;74(5):1094-9.
52. Rouse P, Shaw G, Ahmed HU, Freeman A, Allen C, Emberton M. Multi-parametric magnetic resonance imaging to rule-in and ruleout clinically important prostate cancer in men at risk: a cohort study. Urol Int. 2011;87(1):49-53.
53. Wang L, Akin O, Mazaheri Y, Ishill NM, Kuroiwa K, Zhang J, et al. Are histopathological features of prostate cancer lesions associated with identification of extracapsular extension on magnetic resonance imaging? BJU Int. 2010;106(9):1303-8.
54. Cornud F, Rouanne M, Beuvon F, Eiss D, Flam T, Liberatore M, et al. Endorectal 3D T2-weighted 1 mm-slice thickness MRI for prostate cancer staging at 1.5Tesla: Should we reconsider the indirect signs of extracapsular extension according to the D'Amico tumor risk criteria? Eur J Radiol 2011.
55. Woodfield CA, Tung GA, Grand DJ, Pezzullo JA, Machan JT, Renzulli 2nd JF. Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. AJR Am J Roentgenol. 2010;194(4):W316-22.
56. Nagarajan R, Margolis D, Raman S, Sheng K, King C, Reiter R, et al. Correlation of Gleason scores with diffusion-weighted imaging findings of prostate cancer. AdvUrol. 2012;2012:374805.
57. Nagarajan R, Margolis D, McClure T, Raman S, Thomas MA. Role of endorectal magnetic resonance spectroscopic imaging in two different Gleason scores in prostate cancer. Med PrincPract. 2011;20(5):444-8.
58. Kobus T, Hambrock T. Hulsbergen-van de Kaa CA, Wright AJ, Barentsz JO, Heerschap A, Scheenen TW: In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3 T with an endorectal coil. EurUrol. 2011;60 (5):1074-80.
59. Augustin H, Fritz GA, Ehammer T, Auprich M, Pummer K. Accuracy of 3-Tesla magnetic resonance imaging for the staging of prostate cancer in comparison to the Partin tables. Acta Radiol. 2009;50(5):562-9.
60. Braeckman J, Autier P, Soviany C, Nir R, Nir D, Michielsen D, et al. The accuracy of transrectal ultrasonography supplemented with computer-aided ultrasonography for detecting small prostate cancers. BJU Int. 2008;102(11):1560-5.
61. Xie SW, Li HL, Du J, Xia JG, Guo YF, Xin M, et al. Contrastenhanced ultrasonography with contrast-tuned imaging technology for the detection of prostate cancer: comparison with conventional ultrasonography. BJU Int 2011.
62. Aigner F, Pallwein L, Schocke M, Lebovici A, Junker D, Schafer G, et al. Comparison of real-time sonoelastography with T2- weighted endorectal magnetic resonance imaging for prostate cancer detection. J Ultrasound Med. 2011;30(5):643-9.
63. Brock M, von Bodman C, Sommerer F, Loppenberg B, Klein T, Deix T, et al. Comparison of real-time elastography with grey-scale ultrasonography for detection of organ-confined prostate cancer and extra capsular extension: a prospective analysis using whole mount sections after radical prostatectomy. BJU Int. 2011;108(8 Pt 2):E217-22.
64. Walz J, Marcy M, Pianna JT, Brunelle S, Gravis G, Salem N, et al. Identification of the prostate cancer index lesion by real-time elastography: considerations for focal therapy of prostate cancer. World J Urol. 2011;29(5):589-94.
65. Zhai L, Madden J, Foo WC, Mouraviev V, Polascik TJ, Palmeri ML, et al. Characterizing stiffness of human prostates using acoustic radiation force. Ultrason Imaging. 2010;32(4):201-13.
66. Zhai L, Madden J, Foo WC, Palmeri ML, Mouraviev V, Polascik TJ, et al. Acoustic radiation force impulse imaging of human prostates ex vivo. Ultrasound Med Biol. 2010;36(4):576-88.
67. Tsivian M, Polascik TJ. Focal cryotherapy for prostate cancer. CurrUrol Rep. 2010;11(3):147-51.